Skip to main content
Industry News
EU OKs crizanlizumab to prevent sickle cell disease pain

Novartis' Adakveo, or crizanlizumab, has been approved by the European Commission in combination with hydroxyurea for the prevention of recurrent painful vaso-occlusive crises in people with sickle cell disease ages 16 and older.

Full Story: